Back to top
more

Bicycle Therapeutics (BCYC)

(Delayed Data from NSDQ)

$7.46 USD

7.46
133,921

-0.10 (-1.32%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $7.41 -0.05 (-0.67%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Bicycle Therapeutics PLC Sponsored ADR (BCYC) Is a Great Choice for "Trend" Investors, Here's Why

by Zacks Equity Research

Bicycle Therapeutics PLC Sponsored ADR (BCYC) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Zacks Equity Research

Athenex (ATNX) Skin Treatment Klisyri Gets Approval in Europe

by Zacks Equity Research

Athenex (ATNX) announces approval for its skin treatment drug, Klisyri, in Europe. The company's partner Almirall is set to handle the launch of the drug in the region.

Zacks Equity Research

Albireo (ALBO) Cholestasis Drug Bylvay Gets European Approval

by Zacks Equity Research

Albireo's (ALBO) Bylvay becomes the first and only drug to treat progressive familial intrahepatic cholestasis, following its approval in Europe.

Zacks Equity Research

Ionis (IONS) Inks Deal With Bicycle Therapeutics for LICA Drugs

by Zacks Equity Research

Ionis (IONS) signs a deal with Bicycle Therapeutics to incorporate the latter's optimized Bicycle peptides into its LICA delivery platform.

Zacks Equity Research

Here's What Could Help Bicycle Therapeutics PLC Sponsored ADR (BCYC) Maintain Its Recent Price Strength

by Zacks Equity Research

Bicycle Therapeutics PLC Sponsored ADR (BCYC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Zacks Equity Research

Strength Seen in Bicycle Therapeutics PLC Sponsored ADR (BCYC): Can Its 5.9% Jump Turn into More Strength?

by Zacks Equity Research

Bicycle Therapeutics PLC Sponsored ADR (BCYC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Bicycle Therapeutics (BCYC) Catches Eye: Stock Jumps 8.9%

by Zacks Equity Research

Bicycle Therapeutics (BCYC) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Zacks Equity Research

Bicycle Therapeutics Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Bicycle Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Equity Research

Has Bicycle Therapeutics PLC Sponsored (BCYC) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (BCYC) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for March 16th

by Zacks Equity Research

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 16th.

Zacks Equity Research

Bicycle Therapeutics PLC Sponsored ADR (BCYC) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Bicycle Therapeutics PLC Sponsored ADR (BCYC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Is Bicycle Therapeutics PLC Sponsored (BCYC) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (BCYC) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for March 13th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 13th